IL13 and mycosis fungoides: The clinician submitting the biopsy must communicate the suspected MF and potential anti-IL-13 therapy to the dermatopathologist to ensure appropriate immunohistochemical and TCR studies when hematoxylin and eosin histopathology slides do not meet the criteria for MF.